{
"@context": "https://schema.org",
"@type": "Article",
"headline": "Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective",
"url": "https://www.lexblog.com/2022/03/03/switching-study-concludes-that-transition-from-humira-to-samsung-bioepiss-adalimumab-biosimilar-is-safe-and-effective/",
"identifier": {
"@type": "PropertyValue",
"name": "LexBlog Library record",
"value": "LEX-WK-KT4WN8CX",
"url": "https://www.lexblog.com/lib/KT4WN8CX/"
},
"datePublished": "2022-03-03T16:59:26-05:00",
"dateModified": "2022-03-03T16:59:29-05:00",
"author": {
"@type": "Person",
"name": "Emily Rapalino"
},
"sourceOrganization": {
"@type": "Organization",
"name": "Goodwin Procter"
},
"organizationScope": "at-publication",
"isPartOf": "Big Molecule Watch",
"about": "Health Care and Life Sciences",
"sourceUrl": "https://www.bigmoleculewatch.com/2022/03/03/switching-study-concludes-that-transition-from-humira-to-samsung-bioepiss-adalimumab-biosimilar-is-safe-and-effective/",
"sourceStability": "may-move"
}